Hospital Infection Therapeutics Market by Drug Class, Type, and Geography - Forecast and Analysis 2023-2027

Published: Feb 2023 Pages: 178 SKU: IRTNTR75007

Hospital Infection Therapeutics Market Forecast 2023-2027

The Global Hospital Infection Therapeutics Market size is estimated to grow by USD 3.11 billion at a CAGR of 4.98% between 2022 and 2027. The growth of the market depends on several factors, including an increase in the incidence and prevalence of respiratory disorders, the growing geriatric population, and special drug designations. Market growth is significantly propelled by the rising incidence and prevalence of respiratory disorders, which remain a leading cause of mortality and disease burden globally, alongside other hospital infectious diseases. Conditions like chronic obstructive pulmonary disease (COPD), asthma, and acute respiratory infections are witnessing an uptick in prevalence.

What will be the size of the Hospital Infection Therapeutics Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

This report extensively covers market segmentation by drug class (antibiotics drugs, antifungal drugs, and antiviral drugs), type (respiratory tract infections, surgical site infections, bloodstream infections, gastrointestinal infections, and urinary tract infections), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. 

By Drug Class

The market share growth by the antibiotics drugs segment will be significant during the forecast period. Antibiotics are therapeutic agents that are used for preventing and treating infections that are caused by bacteria and other susceptible microorganisms. The increasing prevalence of infectious diseases globally is driving the growth of the segment during the forecast period.

Get a glance at the market contribution of various segments Request a PDF Sample

The antibiotics drugs segment was valued at USD 5.46 billion in 2017 and continued to grow by 2021. There are two types of antibiotics, namely broad-spectrum and narrow-spectrum antibiotics. Broad-spectrum antibiotics are effective against a wide range of microorganisms. They can be used in cases where bacteria do not respond to narrow-spectrum drugs. Some of the broad-spectrum antibiotics include amoxicillin, levofloxacin, gatifloxacin, streptomycin, tetracycline, and chloramphenicol. Narrow-spectrum antibiotics are active against a few certain groups of bacteria. Some of the narrow-spectrum antibiotics that are commonly used include azithromycin, clarithromycin, clindamycin, erythromycin, and vancomycin. Such factors will drive the growth of the antibiotic drug segment of the global market during the forecast period.

Key Regions

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to account for 36% of the growth of the global hospital acquired infections therapeutic market during the forecast period. 

The growth of the market in the region is attributed to factors such as the increasing incidence of chronic diseases, growth in healthcare expenditure, and the rising preference for therapeutics over surgical procedures. Other factors such as the growing focus of pharmaceutical and biotechnology companies on R&D, the increasing geriatric population, and the presence of global and regional vendors are also driving the regional market.

Market Dynamics and Customer Landscape

The market is pivotal in combating Healthcare-associated infections (HAIs) such as Central line-associated bloodstream infections, Catheter-associated urinary tract infections, and Ventilator-associated pneumonia. Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and urinary tract infections (UTIs) pose significant challenges, driving demand for innovative solutions. The Centers for Disease Control and Prevention (CDC) highlights antimicrobial resistance as a critical concern, necessitating effective therapeutics. However, constraints like high initial investment and reliability issues impede widespread adoption. Nonetheless, incentives for sustainable solutions, driven by environmental consciousness and cost reduction imperatives, offer opportunities. Industries like construction, automotive, and electronics prioritize product quality and sustainability, promoting eco-friendly, renewable solutions to curb carbon emissions. Leveraging economies of scale, the Hospital Infection Therapeutics Market aims for sustainable, effective solutions amidst urbanization and environmental challenges. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The increase in the incidence and prevalence of respiratory disorders is notably driving the market growth. Respiratory diseases are one of the main causes of mortality and disease burden worldwide, among other hospital infectious diseases. The prevalence of diseases such as chronic obstructive pulmonary disease (COPD), asthma, and acute respiratory infections is rising.

Respiratory diseases lead to more than four million deaths in developing countries. Pneumonia accounts for 18% of deaths among children under the age of five years. In the US, more than 534,242 deaths of men and women were due to chronic respiratory diseases. Hence, the rise in the incidence and prevalence of respiratory disorders will drive the growth of the global hospital acquired infections therapeutic market during the forecast period.

Significant Market Trend

The increasing hospital visits is a key trend influencing the market growth. The prevalence of chronic diseases is increasing worldwide, which is increasing the number of visits to hospitals. For instance, according to the CDC, in 2018, around 37,968 people received an HIV diagnosis in the US. In the same year, 7.9% of the patient population in the US stayed overnight in hospitals. Hospitals are a major source of infections, which results in a rise in morbidity and mortality in hospitalized patients. 

The increasing incidence of hospital infectious diseases has created a significant social and economic burden on the healthcare system in countries such as the US and Australia. Moreover, the aging population is increasing globally, especially in countries such as Japan, the UK, the US, and Germany. This will increase the demand for blood culture tests performed on patients, which will support the growth of the hospital-acquired infections therapeutic market during the forecast period.

Major Market Challenge

Stringent regulations may impede market growth. Vendors should adhere to stringent regulations enforced by regulatory authorities such as the US FDA and the EMA to obtain marketing approval for drugs. This can increase the R&D expenditure for drugs. The complicated regulatory process can adversely affect the development of drugs to treat hospital infectious diseases.

Only about one in every 5,000 new drugs reach the open market. The US FDA has also increased the regulatory surveillance of cancer drugs to avoid associated risks. Hence, a failure in drug performance can lead to a delay in receiving marketing approval. Thus, stringent regulations discourage new entrants as well as existing vendors from entering the market with novel therapeutic candidates. These factors will challenge global hospital acquired infections therapeutic market growth during the forecast period.

Key Market Customer Landscape

The report includes the adoption lifecycle of the hospital acquired infections therapeutic market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Hospital Infection Therapeutics Market Players?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the hospital acquired infections therapeutic market.

  • Abbott Laboratories - The company offers hospital infection therapeutics such as Favipiravir.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • AbbVie Inc.
  • Achilles Therapeutics plc
  • AstraZeneca Plc
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Cipla Ltd.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Segment Overview

The report forecasts market growth by revenue at global, regional, and country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Drug Class Outlook
    • Antibiotics drugs
    • Antifungal drugs
    • Antiviral drugs
  • Type Outlook 
    • Respiratory tract infections
    • Surgical site infections
    • Bloodstream infections
    • Gastrointestinal infections
    • Urinary tract infections
  • Region Outlook 
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW
      • Australia
      • Argentina
      • Rest of the world

Market Analyst Overview

The market is witnessing significant growth, driven by the increasing prevalence of healthcare-associated infections (HAIs) such as central line-associated bloodstream infections, catheter-associated urinary tract infections (CAUTI), and ventilator-associated pneumonia. Challenges posed by antimicrobial resistance, particularly from pathogens like Methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii, further underscore the urgent need for effective therapeutics. Start-ups, universities, and research institutes like the Indian Institute of Science Education and Research (IISER) and the Central Drug Research Institute (CSIR-CDRI) are actively involved in developing innovative solutions. Regulatory bodies such as the US Food and Drug Administration (FDA) play a crucial role in ensuring the safety and efficacy of these therapeutics. Sustainability and environmental consciousness are driving forces, with a focus on eco-friendly and renewable solutions amidst global sustainability challenges. However, constraints like high initial investment and supply chain disruptions pose challenges to market growth. Technological advancements, coupled with incentives and increased demand, are expected to shape the future trajectory of the Market.

Moreover, the market is witnessing a surge in demand due to the escalating threat of nosocomially acquired infections, such as Catheter-Associated Urinary Tract Infection (CAUTI) and Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Key players like Innoviva Specialty Therapeutics are innovating solutions to combat acute uncomplicated cystitis and other healthcare-associated infections. Growth drivers include a growing awareness of environmental impacts and the need for cost reduction in healthcare settings. However, challenges such as infrastructure limitations and policy uncertainty pose restraints to market expansion. Influencers like digital technologies and materials play a crucial role in enhancing the efficiency and effectiveness of hospital infection therapeutics. Additionally, industries like construction, automotive, and electronics contribute to the demand for high-quality products, driving production growth rates and volumes in this sector. Measures to address intermittency, reliability, and grid upgrades are imperative, alongside efforts to reduce carbon emissions and reliance on fossil fuels and nuclear energy. Shortages of critical materials further underscore the importance of sustainable solutions in this market segment.

Hospital Infection Therapeutics Market Scope

Report Coverage

Details

Page number

178

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 4.98%

Market growth 2023-2027

USD 3.11 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

4.75

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 36%

Key countries

US, Germany, France, UK, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Abbott Laboratories, AbbVie Inc., Achilles Therapeutics plc, AstraZeneca Plc, Basilea Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Spero Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Market dynamics

Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our market research report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the size of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global hospital infection therapeutics market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global hospital infection therapeutics market 2017 - 2021 ($ million)
    • 4.2 Drug Class Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Drug Class Segment 2017 - 2021 ($ million)
    • 4.3 Type Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Drug Class

    • 6.1 Market segments
      • Exhibit 30: Chart on Drug Class - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Drug Class - Market share 2022-2027 (%)
    • 6.2 Comparison by Drug Class
      • Exhibit 32: Chart on Comparison by Drug Class
      • Exhibit 33: Data Table on Comparison by Drug Class
    • 6.3 Antibiotics drugs - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Antibiotics drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Antibiotics drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Antibiotics drugs - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Antibiotics drugs - Year-over-year growth 2022-2027 (%)
    • 6.4 Antifungal drugs - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Antifungal drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Antifungal drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Antifungal drugs - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Antifungal drugs - Year-over-year growth 2022-2027 (%)
    • 6.5 Antiviral drugs - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Antiviral drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Antiviral drugs - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Antiviral drugs - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Antiviral drugs - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Drug Class
      • Exhibit 46: Market opportunity by Drug Class ($ million)

    7 Market Segmentation by Type

    • 7.1 Market segments
      • Exhibit 47: Chart on Type - Market share 2022-2027 (%)
      • Exhibit 48: Data Table on Type - Market share 2022-2027 (%)
    • 7.2 Comparison by Type
      • Exhibit 49: Chart on Comparison by Type
      • Exhibit 50: Data Table on Comparison by Type
    • 7.3 Respiratory tract infections - Market size and forecast 2022-2027
      • Exhibit 51: Chart on Respiratory tract infections - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Data Table on Respiratory tract infections - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Chart on Respiratory tract infections - Year-over-year growth 2022-2027 (%)
      • Exhibit 54: Data Table on Respiratory tract infections - Year-over-year growth 2022-2027 (%)
    • 7.4 Surgical site infections - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Surgical site infections - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on Surgical site infections - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on Surgical site infections - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Surgical site infections - Year-over-year growth 2022-2027 (%)
    • 7.5 Bloodstream infections - Market size and forecast 2022-2027
      • Exhibit 59: Chart on Bloodstream infections - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Data Table on Bloodstream infections - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Chart on Bloodstream infections - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on Bloodstream infections - Year-over-year growth 2022-2027 (%)
    • 7.6 Gastrointestinal infections - Market size and forecast 2022-2027
      • Exhibit 63: Chart on Gastrointestinal infections - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Data Table on Gastrointestinal infections - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Chart on Gastrointestinal infections - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on Gastrointestinal infections - Year-over-year growth 2022-2027 (%)
    • 7.7 Urinary tract infections - Market size and forecast 2022-2027
      • Exhibit 67: Chart on Urinary tract infections - Market size and forecast 2022-2027 ($ million)
      • Exhibit 68: Data Table on Urinary tract infections - Market size and forecast 2022-2027 ($ million)
      • Exhibit 69: Chart on Urinary tract infections - Year-over-year growth 2022-2027 (%)
      • Exhibit 70: Data Table on Urinary tract infections - Year-over-year growth 2022-2027 (%)
    • 7.8 Market opportunity by Type
      • Exhibit 71: Market opportunity by Type ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 73: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 74: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 75: Chart on Geographic comparison
      • Exhibit 76: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 77: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 93: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Germany - Market size and forecast 2022-2027
      • Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.9 China - Market size and forecast 2022-2027
      • Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.10 France - Market size and forecast 2022-2027
      • Exhibit 105: Chart on France - Market size and forecast 2022-2027 ($ million)
      • Exhibit 106: Data Table on France - Market size and forecast 2022-2027 ($ million)
      • Exhibit 107: Chart on France - Year-over-year growth 2022-2027 (%)
      • Exhibit 108: Data Table on France - Year-over-year growth 2022-2027 (%)
    • 9.11 UK - Market size and forecast 2022-2027
      • Exhibit 109: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 110: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 111: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 112: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 113: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 114: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 115: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 116: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 117: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 118: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 119: Matrix on vendor position and classification
            • 12.3 Abbott Laboratories
              • Exhibit 120: Abbott Laboratories - Overview
              • Exhibit 121: Abbott Laboratories - Business segments
              • Exhibit 122: Abbott Laboratories - Key news
              • Exhibit 123: Abbott Laboratories - Key offerings
              • Exhibit 124: Abbott Laboratories - Segment focus
            • 12.4 AbbVie Inc.
              • Exhibit 125: AbbVie Inc. - Overview
              • Exhibit 126: AbbVie Inc. - Product / Service
              • Exhibit 127: AbbVie Inc. - Key news
              • Exhibit 128: AbbVie Inc. - Key offerings
            • 12.5 Achilles Therapeutics plc
              • Exhibit 129: Achilles Therapeutics plc - Overview
              • Exhibit 130: Achilles Therapeutics plc - Product / Service
              • Exhibit 131: Achilles Therapeutics plc - Key offerings
            • 12.6 AstraZeneca Plc
              • Exhibit 132: AstraZeneca Plc - Overview
              • Exhibit 133: AstraZeneca Plc - Product / Service
              • Exhibit 134: AstraZeneca Plc - Key news
              • Exhibit 135: AstraZeneca Plc - Key offerings
            • 12.7 Bayer AG
              • Exhibit 136: Bayer AG - Overview
              • Exhibit 137: Bayer AG - Business segments
              • Exhibit 138: Bayer AG - Key news
              • Exhibit 139: Bayer AG - Key offerings
              • Exhibit 140: Bayer AG - Segment focus
            • 12.8 Bristol Myers Squibb Co.
              • Exhibit 141: Bristol Myers Squibb Co. - Overview
              • Exhibit 142: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 143: Bristol Myers Squibb Co. - Key news
              • Exhibit 144: Bristol Myers Squibb Co. - Key offerings
            • 12.9 F. Hoffmann La Roche Ltd.
              • Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.10 Gilead Sciences Inc.
              • Exhibit 150: Gilead Sciences Inc. - Overview
              • Exhibit 151: Gilead Sciences Inc. - Product / Service
              • Exhibit 152: Gilead Sciences Inc. - Key news
              • Exhibit 153: Gilead Sciences Inc. - Key offerings
            • 12.11 GlaxoSmithKline Plc
              • Exhibit 154: GlaxoSmithKline Plc - Overview
              • Exhibit 155: GlaxoSmithKline Plc - Business segments
              • Exhibit 156: GlaxoSmithKline Plc - Key offerings
              • Exhibit 157: GlaxoSmithKline Plc - Segment focus
            • 12.12 Johnson and Johnson
              • Exhibit 158: Johnson and Johnson - Overview
              • Exhibit 159: Johnson and Johnson - Business segments
              • Exhibit 160: Johnson and Johnson - Key news
              • Exhibit 161: Johnson and Johnson - Key offerings
              • Exhibit 162: Johnson and Johnson - Segment focus
            • 12.13 Merck and Co. Inc.
              • Exhibit 163: Merck and Co. Inc. - Overview
              • Exhibit 164: Merck and Co. Inc. - Business segments
              • Exhibit 165: Merck and Co. Inc. - Key news
              • Exhibit 166: Merck and Co. Inc. - Key offerings
              • Exhibit 167: Merck and Co. Inc. - Segment focus
            • 12.14 Novartis AG
              • Exhibit 168: Novartis AG - Overview
              • Exhibit 169: Novartis AG - Business segments
              • Exhibit 170: Novartis AG - Key offerings
              • Exhibit 171: Novartis AG - Segment focus
            • 12.15 Pfizer Inc.
              • Exhibit 172: Pfizer Inc. - Overview
              • Exhibit 173: Pfizer Inc. - Product / Service
              • Exhibit 174: Pfizer Inc. - Key news
              • Exhibit 175: Pfizer Inc. - Key offerings
            • 12.16 Sanofi SA
              • Exhibit 176: Sanofi SA - Overview
              • Exhibit 177: Sanofi SA - Business segments
              • Exhibit 178: Sanofi SA - Key news
              • Exhibit 179: Sanofi SA - Key offerings
              • Exhibit 180: Sanofi SA - Segment focus
            • 12.17 Viatris Inc.
              • Exhibit 181: Viatris Inc. - Overview
              • Exhibit 182: Viatris Inc. - Business segments
              • Exhibit 183: Viatris Inc. - Key offerings
              • Exhibit 184: Viatris Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 185: Inclusions checklist
                • Exhibit 186: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 187: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 188: Research methodology
                • Exhibit 189: Validation techniques employed for market sizing
                • Exhibit 190: Information sources
              • 13.5 List of abbreviations
                • Exhibit 191: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              hospital infection therapeutics market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis